[Br:1][C:2]1[N:7]=[CH:6][C:5]2[CH:8]=[C:9]([C:11]3[CH:12]=[N:13][N:14]([CH3:16])[CH:15]=3)[NH:10][C:4]=2[CH:3]=1.C[Si](C)(C)[N-][Si](C)(C)C.[Na+].[CH2:27]1[CH2:31]O[CH2:29][CH2:28]1.BrCC1CC1>CN(C=O)C.C(OCC)(=O)C.C1(C)C=CC=CC=1>[Br:1][C:2]1[N:7]=[CH:6][C:5]2[CH:8]=[C:9]([C:11]3[CH:12]=[N:13][N:14]([CH3:16])[CH:15]=3)[N:10]([CH2:29][CH:28]3[CH2:31][CH2:27]3)[C:4]=2[CH:3]=1
6-Bromo-2-(1-methyl-1H-pyrazol-4-yl)-1H-pyrrolo[3,2-c]pyridine (Preparation 22, 100 mg, 0.36 mmole) was azeotroped with toluene (3 mL) and dissolved in DMF (1 mL). To the solution was added sodium hexamethyldisilazide, 1M in THF (0.4 mL, 0.4 mmole) and the reaction was stirred at room temperature for 20 minutes. Bromomethylcyclopropane (78 uL, 108 mg, 0.8 mmole) was added and the reaction was stirred at room temperature for 6 hours. Ethyl acetate (25 mL) was added and the solution was washed with water (3×10 mL) and with brine (5 mL), dried and evaporated in vacuo. The crude product was purified using preparative TLC eluting with ethyl acetate to afford the title compound (98 mg, 82%). 1H-NMR (CDCl3, 500 MHz): δ 0.23 (m, 2H), 0.55 (m, 2H), 1.12 (m, 1H), 4.03 (s, 3H), 4.07 (d, J=6.31 Hz, 2H), 6.54 (d, J=0.95 Hz, 1H), 7.45 (t, J=0.95 Hz, 1H), 7.61 (s, 1H), 7.71 (d, J=0.95 Hz, 1H), 8.61 (d, J=0.95 Hz, 1H).
読み込み中…
